Shelton R J, Clark A L, Goode K, Rigby A S, Houghton T, Kaye G C, Cleland J G F
Department of Cardiology, Castle Hill Hospital, Kingston-upon-Hull, UK.
Heart. 2009 Jun;95(11):924-30. doi: 10.1136/hrt.2008.158931. Epub 2009 Mar 11.
Atrial fibrillation (AF) and heart failure (HF) often coexist. The aim was to investigate whether restoring sinus rhythm (SR) could improve cardiac function, symptoms, exercise capacity and quality of life (QoL) in patients with chronic heart failure.
Patients with HF and persistent AF receiving guideline-recommended treatments, including anticoagulants, were eligible for the study. Patients were randomised to either rhythm (treated with amiodarone for at least 3 months prior to attempting biphasic external cardioversion and continued amiodarone long-term if SR was restored) or rate control. Anticoagulants were continued throughout the study regardless of rhythm, unless contraindications developed. Both groups were treated with beta blockers and/or digoxin to reduce the heart rate to <80 bpm at rest and <110 bpm after walking. Symptoms, walk distance (6-minute corridor walk test, 6MWT), QoL and cardiac function were assessed at baseline and 1 year.
61 patients with HF and persistent AF (median duration 14 months (IQR 5 to 32)) were randomly assigned to a rate or rhythm control strategy. Of patients assigned to rhythm control (n = 30), 66% were in SR at 1 year, and 90% of those assigned to rate control (n = 31) achieved the heart rate target. At 1 year, NYHA class (p = 0.424) and 6MWT distance (p = 0.342) were similar between groups but patients assigned to rhythm control had improved LV function (p = 0.014), NT-proBNP concentration (p = 0.046) and QoL (p = 0.019) compared with those assigned to rate control. Greatest improvement was seen in patients in whom SR was maintained.
Restoring SR in patients with AF and heart failure may improve QoL and LV function when compared with a strategy of rate control.
心房颤动(AF)与心力衰竭(HF)常并存。本研究旨在探讨恢复窦性心律(SR)是否能改善慢性心力衰竭患者的心脏功能、症状、运动能力及生活质量(QoL)。
接受包括抗凝剂在内的指南推荐治疗的HF和持续性AF患者符合本研究条件。患者被随机分为节律控制组(在尝试双相体外心脏复律前至少用胺碘酮治疗3个月,若恢复SR则长期继续使用胺碘酮)或心率控制组。无论节律如何,整个研究过程中均持续使用抗凝剂,除非出现禁忌证。两组均使用β受体阻滞剂和/或地高辛将静息心率降至<80次/分钟,步行后心率降至<110次/分钟。在基线和1年时评估症状、步行距离(6分钟走廊步行试验,6MWT)、QoL和心脏功能。
61例HF和持续性AF患者(中位病程14个月(IQR 5至32))被随机分配至心率或节律控制策略组。在分配至节律控制组的患者(n = 30)中,1年时66%恢复SR,分配至心率控制组的患者(n = 31)中90%达到心率目标。1年时,两组间纽约心脏协会(NYHA)分级(p = 0.424)和6MWT距离(p = 0.342)相似,但与心率控制组相比,分配至节律控制组的患者左心室功能(p = 0.014)、N末端B型利钠肽原(NT-proBNP)浓度(p = 0.046)和QoL(p = 0.019)有所改善。维持SR的患者改善最为明显。
与心率控制策略相比,恢复AF和心力衰竭患者的SR可能改善QoL和左心室功能。